Introduction {#sec1-1}
============

Despite advances in diagnosis and treatment, coronary heart disease (CHD) is most common cause of mortality in both developing and developed countries. Among the common and severe forms of CHD is acute coronary syndrome (ACS), which includes unstable angina pectoris, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction ([@ref1]). Atherosclerosis is a chronic inflammatory process, and inflammation is a vital element of ACS ([@ref2]). Platelets are a source of inflammatory mediators ([@ref3]). Increased platelet activation is known to trigger atherosclerosis and plays a major role in its progression ([@ref4]). Elevated peripheral blood platelet count is closely related to major adverse cardiovascular outcomes ([@ref5], [@ref6]). Lymphocytes have been shown to modulate the immunologic response at all stages of the atherosclerotic process ([@ref7]). The association between low lymphocyte count and major adverse cardiovascular outcomes was also shown in several studies ([@ref8]-[@ref10]).

Previous studies revealed a significant relationship between hematologic parameters, especially neutrophil-to-lymphocyte ratio (NLR), and CHD. The predictive and prognostic value of the NLR has been demonstrated in several cardiovascular diseases ([@ref11]-[@ref15]). Although preliminary data have shown that the platelet-to-lymphocyte ratio (PLR) is associated with major adverse cardiovascular outcomes and some cancers, there are not enough data, especially in cardiovascular disease ([@ref16]-[@ref18]). Therefore, the aim of this study was to explore the association between PLR and in-hospital mortality in patients with acute coronary syndrome.

Methods {#sec1-2}
=======

Study population {#sec2-1}
----------------

The present study is a single-center, observational study. We retrospectively collected patients with ACS undergoing coronary angiography between January 2012 and August 2013.

Exclusion criteria were cardiogenic shock, significant valvular heart disease, hematological disease, malignancy, severe liver or renal disease, systemic inflammatory disease or active infection, and autoimmune disease. The study was approved by the local ethics committee.

Definitions {#sec2-2}
-----------

Acute coronary syndrome was defined as presentation with symptoms of ischemia in association with electrocardiographic changes or positive cardiac enzymes ([@ref1]). Arterial hypertension was considered in patients with repeated blood pressure measurements \>140/90 mm Hg or active use of antihypertensive drugs. Diabetes mellitus was defined as fasting plasma glucose levels more than 126 mg/dL in multiple measurements or active use of antidiabetic medications. Smoking was defined as current smoking. Patients having fever or symptoms or signs of urinary tract or respiratory system infection (leukocytosis or nitrite positivity in urine, infiltration in chest x-ray) were defined as active infection. PLR was calculated as the ratio of platelet count to lymphocyte count.

Biochemical and hematological parameters {#sec2-3}
----------------------------------------

Peripheral venous blood samples were drawn on admission to the emergency room. Total and differential leukocyte counts were measured by an automated hematology analyzer (Abbott Cell-Dyn 3700; Abbott Laboratory, Abbott Park, Illinois, USA). Routine biochemical tests were performed by standard techniques.

Statistical analysis {#sec2-4}
--------------------

Data were analyzed with SPSS software, version 18.0 for Windows (SPSS Inc, Chicago, Illinois, USA). The Kolmogorov- Smirnov test was used to verify the normality of the distribution of continuous variables. Continuous variables were defined as means±standard deviation; categorical variables were given as percentages. Comparison among multiple groups was performed by Kruskal-Wallis test or one-way analysis of variance (ANOVA) test, and the chi-square Fisher exact test was carried out for categorical variables as appropriate. For the post-hoc analysis, either the Scheffe or Mann-Whitney U test was performed. Statistical significance was defined as p\<0.05. Variables for which the p value was \<0.05 in the univariate analysis were assessed by multiple logistic regression analysis to evaluate the independent predictors of in-hospital mortality. All variables found to be significant in the univariate analysis were included in the logistic regression model, and the results are shown as odds ratio (OR) with 95% confidence intervals (CIs). Receiver operating characteristic (ROC) curve analysis was used to determine the optimum cut-off levels of the PLR in association with in-hospital mortality.

Results {#sec1-3}
=======

In total, 587 patients with a mean age of 61.8±13.1 years (68.4% male) were enrolled in the study. Patients were divided into 3 tertiles based on PLR levels: 83.9±15.4 in tertile 1, 127.0±13.8 in tertile 2, and 214.0±71.8 in tertile 3. According to the PLR tertiles, the baseline demographic, hematological, and angiographic parameters of the patients are shown in [Table 1](#T1){ref-type="table"}. In-hospital mortality was significantly higher among patients in the upper PLR tertile when compared with the middle and lower PLR tertile groups \[29 (14.8%) vs. 17 (8.7%) and 2 (1.0%); p\<0.001, respectively; [Fig. 1](#F1){ref-type="fig"}\].

###### 

Clinical, hematologic, and angiographic characteristics of population with acute coronary syndrome according to platelet-to-lymphocyte ratio tertiles

  Variables                                         PLR                                                       
  ------------------------------------------------- ------------------ ------------------ ------------------- ------------------------------------------
  Age, years (%)                                    59.0±12.2          61.7±12.7          64.7±13.7           \<0.001^[a](#t1f1){ref-type="table-fn"}^
  Male gender, n (%)                                139 (71.3)         133(67.9)          129 (66.2)          0.540
  Hypertension, n (%)                               84 (43.1)          82 (41.8)          101 (51.5)          0.111
  Diabetes mellitus, n (%)                          38 (19.5)          54 (27.6)          59 (30.1)           0.043
  Smoking, n (%)                                    74 (37.9)          81 (41.3)          77 (39.3)           0.789
  Previous MI history, n (%)                        23 (11.8)          32 (16.3)          27 (13.8)           0.432
  Hemoglobin, g/dL                                  14.0± 1.5          14.0±1.6           13.6±1.7            0.008^[b](#t1f2){ref-type="table-fn"}^
  White blood cell count, 10^3^/μL                  11.5±3.2           11.4±3.5           12.1±4.3            0.133
  Neutrophil count, 10^3^/μL                        7.6±2.9            8.5±3.3            9.9±4.3             \<0.001^[c](#t1f3){ref-type="table-fn"}^
  Lymphocyte count, 10^3^/μL                        2.8±0.8            2.0±0.5            1.4±0.5             \<0.001^[d](#t1f4){ref-type="table-fn"}^
  Platelet count, 10^3^/μL                          232.0±53.9         257.1±54.5         286.1±67.5          \<0.001^[e](#t1f5){ref-type="table-fn"}^
  Creatinine, mg/dL                                 0.79 (0.72-0.94)   0.81 (0.70-0.94)   0.83 (0.72-1.05)    0.133
  NLR                                               2.50 (1.86-3.57)   4.11 (2.88-5.46)   7.04 (4.57-10.15)   \<0.001^[f](#t1f6){ref-type="table-fn"}^
  CRP, mg/dL                                        0.52 (0.31-1.08)   0.62 (0.35-1.00)   0.64 (0.39-1.39)    0.287
  Total cholesterol, mg/dL                          179.3±39.3         181.3±44.1         173.7 ± 38.0        0.168
  Triglyceride, mg/dL                               138(91-205)        135 (91-195)       116 (80-170)        0.008^[g](#t1f7){ref-type="table-fn"}^
  LDL, mg/dL                                        110.9±31.3         114.0±36.9         111.0±32.0          0.595
  HDL, mg/dL                                        34.6±8.2           36.3±9.7           35.1±10.3           0.207
  Left ventricular EF, %                            50(45-55)          46 (40-55)         45 (40-50)          \<0.001^[h](#t1f8){ref-type="table-fn"}^
  **Number of stenosed coronary arteries, n (%)**                                                             0.888
   Single vessel                                    84 (43.1)          81 (41.3)          80 (40.8)           
   Two vessel                                       64 (32.8)          59 (30.1)          63 (32.1)           
   Three vessel                                     47 (24.1)          56 (28.6)          53 (27.0)           
  **Type of acute coronary syndrome, n (%)**                                                                  \<0.001
   USAP                                             28 (14.4)          18 (9.2)           18 (9.2)            
   NSTEMI                                           71 (36.4)          54 (27.6)          36 (18.4)           
   STEMI                                            96 (49.2)          124 (63.3)         142 (72.4)          
  **Culprit vessel, n (%)**                                                                                   0.298
   LAD                                              86 (44.1)          89 (45.4)          95 (48.5)           
   Cx                                               55 (28.2)          55 (28.1)          39 (19.9)           
   RCA                                              54 (27.7)          52 (26.5)          62 (31.6)           
   In-hospital mortality, n (%)                     2 (1.0)            17 (8.7)           29 (14.8)           \<0.001

Data are presented as number (percentage) and mean±standard deviation or median (interquartile range) values For post hoc analysis either Scheffe or Mann-Whitney U test was performed \*ANOVA and Kruskal-Wallis tests

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p=0.134, p\<0.001, and p=0.064, respectively)

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p=0.893, p=0.015, and p=0.051, respectively)

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p=0.051, p\<0.001, and p=0.001, respectively)

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p\<0.001, p\<0.001, and p\<0.001, respectively)

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p\<0.001, p\<0.001, and p\<0.001, respectively)

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p\<0.001, p\<0.001, and p\<0.001, respectively)

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p=0.583, p=0.004, and p=0.013, respectively)

(1 vs. 2, 1 vs. 3, and 2 vs. 3 p=0.014, p\<0.001, and p=0.057, respectively)

CRP - C-reactive protein; Cx - circumflex; EF - ejection fraction; HDL - high-density lipoprotein; LAD - left anterior descending; LDL - low-density lipoprotein; MI - myocardial infarction; NLR - neutrophil-to-lymphocyte ratio; NSTEMI - non-ST-segment elevation myocardial infarction; PLR - platelet-to-lymphocyte ratio; RCA - right coronary artery; STEMI - ST-segment elevation myocardial infarction; USAP - unstable angina pectoris. CRP values were available for 247 patients
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In the multiple logistic regression analysis, a high level of PLR was an independent predictor of in-hospital mortality (OR: 1.012, 95% CI: 1.005-1.019, p\<0.001), together with age (OR: 1.045, 95% CI: 1.005-1.087, p=0.027), WBC count (OR: 1.251, 95% CI: 1.108-1.412, p\<0.001), and creatinine (OR: 3.541, 95% CI: 1.558-8.047, p=0.003; [Table 2](#T2){ref-type="table"}). In the ROC analysis, PLR \>142 had 69% sensitivity and 63% specificity (ROC area under curve: 0.756, 95% CI: 0.691-0.822, p\<0.001) and NLR \>4.55 had 79% sensitivity and 61% specificity in accurately predicting a diagnosis of in-hospital mortality (ROC area under curve: 0.778, 95% CI: 0.709-0.847, p\<0.001; [Fig. 2](#F2){ref-type="fig"}).

###### 

Significant predictors of in-hospital mortality in univariable and multiple logistic regression analyses

  Variables                           Univariate analysis   Multiple logistic regression analysis                         
  ----------------------------------- --------------------- --------------------------------------- --------------------- ---------
  Age                                 1.060 (1.033-1.088)   \<0.001                                 1.045 (1.005-1.087)   0.027
  Male gender                         0.541 (0.296-0.990)   0.046                                   0.546 (0.217-1373)    0.198
  Left ventricular EF                 0.924 (0.895-0.954)   \<0.001                                 0.980 (0.935-1.028)   0.414
  PLR                                 1.014 (1.009-1.019)   \<0.001                                 1.012 (1.005-1.019)   \<0.001
  Hypertension                        0.750 (0.415-1.354)   0.339                                                         
  LAD as the infarct-related artery   1.191 (0.660-2.150)   0.562                                                         
  STEMI as the cause of ACS           3.370 (1.547-7.339)   0.002                                   0.446 (0.128-1.549)   0.203
  Multivessel disease                 3.924 (1.802-8.542)   \<0.001                                 1.959 (0.717-5.349)   0.190
  Diabetes mellitus                   2.020 (1.097-3.721)   0.024                                   1.099 (0.436-2.775)   0.841
  Smoking                             0.748 (0.400-1.396)   0.361                                                         
  Previous MI history                 2.530 (1.275-5.019)   0.008                                   0.395 (0.122-1.285)   0.123
  Hemoglobin                          0.914 (0.763-1.096)   0.332                                                         
  White blood cell                    1.180 (1.096-1270)    \<0.001                                 1.251 (1.108-1412)    \<0.001
  RDW                                 1.204 (0.975-1.487)   0.084                                                         
  Creatinine                          2.859 (1.550-5.273)   0.001                                   3.541 (1.558-8.047)   0.003
  LDL                                 0.987 (0.975-0.998)   0.019                                   0.993 (0.978-1.009)   0.382
  HDL                                 0.934 (0.895-0.974)   0.002                                   0.963 (0.923-1.004)   0.080
  Triglyceride                        0.997 (0.992-1.001)   0.166                                                         

ACS - acute coronary syndrome; EF - ejection fraction; HDL - high-density lipoprotein; LAD - left anterior descending; LDL - low-density lipoprotein; MI - myocardial infarction; OR - odds ratio; PLR - platelet-to-lymphocyte ratio; RDW - reticulocyte distribution width; STEMI - ST-segment elevation myocardial infarction.
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Discussion {#sec1-4}
==========

The present study focused more on the assessment of the relation between admission PLR and in-hospital mortality in patients with ACS. We demonstrated that higher PLR is a significant independent predictor of in-hospital mortality in patients with ACS. Moreover, our study showed that a PLR \>142 predicted in-hospital mortality with a sensitivity of 69% and specificity of 63%. Although there was a higher frequency of several cardiovascular risk factors among patients with high PLR, this did not influence the significant association between PLR and in-hospital mortality in the multiple logistic regression analysis.

There are multiple factors in the development and progression of atherosclerosis. Inflammation has a major role at all stages of atherosclerosis, including initiation, progression, and in the thrombotic complications of this disease ([@ref2]). As the understanding of the role of inflammation in the atherosclerotic process gets better, studies have focused on inflammatory markers for improved evaluation of the risk ([@ref19]). White blood cell (WBC) count, leukocyte subtype, platelet, C-reactive protein (CRP), and the NLR are some of the inflammatory markers that have been demonstrated to have predictive and prognostic significance in cardiovascular diseases ([@ref5]-[@ref7], [@ref11]-[@ref15], [@ref20], [@ref21]).

The relationship between white blood cell count and increased cardiovascular risk is well established. While high neutrophil counts reflect the inflammatory response, low lymphocyte counts reflect poor general health and physiologic stress ([@ref22]). Zouridakis et al. ([@ref23]) studied patients with unstable angina and reported that a low lymphocyte count is associated with a significantly higher risk of future cardiac events. There is no clear understanding of the pathogenetic mechanisms underlying these findings. However, lymphocyte count was shown to be an early marker of physiologic stress and systemic failure, secondary to myocardial ischemia mediated by cortisol release ([@ref8], [@ref24]). On the other hand, an elevated lymphocyte count may also show a more appropriate immune response that leads to a better outcome in unstable angina patients ([@ref25]).

The role of platelets in the pathogenesis of ACS has been proven by studies that have shown significant clinical improvement associated with antiplatelet therapy ([@ref26]-[@ref28]). The mechanisms underlying the association of high platelet counts and poor clinical outcomes seem to be multifactorial. High platelet counts may indicate a higher degree of antiplatelet drug resistance and a higher tendency to form platelet-rich thrombi in atherosclerotic plaques, resulting in poor outcomes. Moreover, higher platelet counts may reflect underlying inflammation, as several inflammatory mediators stimulate megakaryocyte proliferation and lead to relative thrombocytosis. Recent researchers have stated that platelets interact with endothelial cells and leukocytes and release inflammatory mediators that cause adhesion and transmigration of monocytes ([@ref29], [@ref30]). These monocytes are also reported to propagate inflammatory processes in the vessel wall, promoting atherosclerotic lesions ([@ref31]).

PLR is derived from the number of platelets and lymphocytes, and it is accepted as a new inflammatory marker ([@ref16]-[@ref18]). It reflects both hyperactive coagulation and inflammatory pathways; it may be a better predictor of impaired perfusion than either the individual platelet or lymphocyte count. More recent studies have stated that higher platelet and lower lymphocyte counts play a major role in adverse cardiovascular outcomes. Azab et al. ([@ref16]) demonstrated a higher value of the PLR as a marker of long-term mortality in patients with non-ST-segment elevation myocardial infarction. Furthermore, Sünbül et al. ([@ref32]) found that the PLR was a significant predictor of non-dipper status in patients with hypertension. Gary et al. ([@ref33]) revealed that increased PLR is significantly associated with patients at high risk for critical limb ischemia. In addition to its prognostic significance, the PLR has also been demonstrated in patients with various cancers ([@ref34], [@ref35]). In a relatively recent study in patients with small cell carcinoma of the esophagus, PLR was proven to be superior to NLR in terms of relapse-free survival and overall survival ([@ref36]).

In our study, age, presence of DM, left ventricular ejection fraction, and NLR were significantly different among patients in the upper PLR tertile when compared with the lower PLR tertile group. This difference can be explained by inflammation, as all of these conditions are associated with increased inflammatory status of the body. Aging is related with increased levels of serum IL-6 and TNF alpha, so that this chronic low-grade inflammation is often called inflammaging ([@ref37]). Similarly, inflammation has a crucial role in the pathogenesis and progression of DM and heart failure ([@ref38], [@ref39]).

In previous studies, higher levels of NLR were demonstrated to be a predictor of short- and long-term mortality in patients with ACS ([@ref15], [@ref40]). Various inflammatory stimuli cause neutrophils to produce different cytokines and cytotoxic/proteolytic enzymes. Through certain mechanisms, including induction of damage to endothelial cells, induction of the coagulation system, aggregation with leukocytic cells, plugging the microvascu-lature, increasing infarct expansion, and leading to cardiac electrical instability, these enzymes affect the cardiovascular system ([@ref41]). The relative lymphopenia seen in ischemia was attributed to increased cortisol levels as a result of physiological stress ([@ref8], [@ref24]). Therefore, NLR may be considered an inflammatory marker in patients with cardiovascular disease.

Patients with chronic renal disease who present with ACS are at increased risk for both adverse cardiovascular outcomes and death compared to those with normal renal function ([@ref42]-[@ref44]). Ahmed et al. ([@ref45]) demonstrated that older patients had a higher risk of adverse hospital outcomes and short- and long-term mortality rates with respect to younger patients. As shown in previous studies, we found that renal dysfunction, together with age and PLR, is independently related with inhospital mortality.

The determination of high-risk patients in terms of in-hospital mortality in acute coronary syndrome is crucial in daily practice. These risky patients require close follow-up and aggressive treatment in order to decrease their mortality. In this context, PLR may contribute to the traditional predictors being used in current risk scoring systems to estimate the in-hospital mortality risk of patients admitted with ACS.

Study limitations {#sec1-5}
=================

Our study had some limitations. This study was conducted on a retrospective basis and represented a single-center experience. It would be better if we had followed the patients and explored the association between adverse long-term cardiac events and PLR in these patients. The use of a single blood sample at admission does not anticipate the persistence of PLR over time.

Conclusion {#sec1-6}
==========

We found PLR to be a risk variable for in-hospital mortality in patient with ACS. Further large-scale, prospective, and multicenter studies are needed to clarify and confirm the association between the PLR and in-hospital mortality in patients with ACS. In conclusion, different from other inflammatory markers and assays, PLR is an inexpensive and readily available biomarker that may be useful for cardiac risk stratification in patients with ACS.
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